Skip to navigationSkip to content
BATCHES TO BATCHES

Why Kodak is perfectly positioned to pivot to pharmaceuticals

the towers of one of kodak's chemical factories.
Reuters/Adam Fenster
Switching up the ingredients.
  • Katherine Ellen Foley
By Katherine Ellen Foley

Health and science reporter

Published

Last week, the US federal government announced a first-of-its-kind loan to Eastman Kodak, a US-based company once known for its leadership in the film photography industry. Kodak will be using the $765 million to begin producing components for generic drugs—specifically, active pharmaceutical ingredients (APIs), the chemicals that make a drug work.

Which raises the question: What’s a photography company got to do with pharmaceuticals?

Chemically speaking, probably a lot. “In the world of chemicals, we have a lot of chemicals that are building blocks—like LEGOs,” says Frankie Wood-Black, a physical chemist currently teaching at Northern Oklahoma College who has 25 years of experience in industrial chemical manufacturing.

Enrich your perspective. Embolden your work. Become a Quartz member.

Your membership supports a team of global Quartz journalists reporting on the forces shaping our world. We make sense of accelerating change and help you get ahead of it with business news for the next era, not just the next hour. Subscribe to Quartz today.

Membership includes:

こちらは英語版への登録ページです。
Quartz Japanへの登録をご希望の方はこちらから。